Dr. Martin Luther King Jr.’s “I Have a Dream” address at 1963’s March on Washington is perhaps the most famous speech in American history. But fewer people remember the man behind King’s dream ...
From call-in radio shows to corner bars, the accent that defined Boston is losing ground. A Dartmouth linguist has research ...
It's Blossom on MSN
Major employers signal layoffs in January
Over 100 employers nationwide have filed notices announcing plans to cut jobs in January 2026, according to WARNTracker.com ...
Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to pick the first fruits from the pact. Gilead is paying $35 million upfront ...
Bay Area drugmaker Gilead Sciences has promoted longtime company attorney Keeley Wettan to executive vice president, general counsel, legal and compliance, effective immediately. Wettan, who joined ...
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based ...
Add Yahoo as a preferred source to see more of our stories on Google. Logos of Gilead at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Hulu has unveiled a first look at “The Testaments,” the upcoming sequel series to “The Handmaid’s Tale.” The series, which is set to premiere in April 2026, is based on “The Handmaid’s Tale” author ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The development, in the works ...
Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results driving optimism for continued growth. Gilead Sciences' key growth drivers include robust sales from Livdelzi and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback